Orkambi

Active Ingredient(s): Lumacaftor + Ivacaftor
FDA Approved: * July 2, 2015
Pharm Company: * VERTEX PHARMS INC
Category: Genetic Disorders

Lumacaftor/ivacaftor, sold under the brand name Orkambi among others, is a combination of lumacaftor and ivacaftor used to treat people with cystic fibrosis who have two copies of the F508del mutation.[3] It is unclear if it is useful in cystic fibrosis due to other causes.[3] It is taken by mouth.[3] Common side effects include shortness of breath, nausea, diarrhea, feeling tired, hearing problems, and rash.[3][4]... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Orkambi Oral Granule
NDC: 51167-122
Labeler:
Vertex Pharmaceuticals Incorporated
Orkambi Oral Granule
NDC: 51167-500
Labeler:
Vertex Pharmaceuticals Incorporated
Orkambi Oral Tablet, Film Coated
NDC: 51167-700
Labeler:
Vertex Pharmaceuticals Incorporated
Orkambi Oral Tablet, Film Coated
NDC: 51167-809
Labeler:
Vertex Pharmaceuticals Incorporated
Orkambi Oral Granule
NDC: 51167-900
Labeler:
Vertex Pharmaceuticals Incorporated